Showing results (11-20 of 18) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Cancer Research|April 18, 2001
Unusual potency of BN 80915, a novel fluorinated E-ring modified camptothecin, toward human colon carcinoma cellsA K Larsen, C Gilbert, G Chyzak, et al.Bioorganic & Medicinal Chemistry Letters|September 25, 1999
BN 80927: a novel homocamptothecin with inhibitory activities on both topoisomerase I and topoisomerase IIO Lavergne, J Harnett, A Rolland, et al.Molecular Pharmacology|August 15, 2001
Apoptosis induced by the homocamptothecin anticancer drug BN80915 in HL-60 cellsA Lansiaux, M Facompré, N Wattez, et al.Cancer Research|June 26, 1999
Homocamptothecin, an E-ring modified camptothecin with enhanced lactone stability, retains topoisomerase I-targeted activity and antitumor propertiesL Lesueur-Ginot, D Demarquay, R Kiss, et al.Anti-Cancer Drugs|March 29, 2001
The homocamptothecin BN 80915 is a highly potent orally active topoisomerase I poisonD Demarquay, M Huchet, H Coulomb, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2000
Homocamptothecin, an E-ring-modified camptothecin, exerts more potent antiproliferative activity than other topoisomerase I inhibitors in human colon cancers obtained from surgery and maintained in vitro under histotypical culture conditionsP Philippart, L Harper, C Chaboteaux, et al.Journal of Medicinal Chemistry|June 8, 2000
Topoisomerase I-mediated antiproliferative activity of enantiomerically pure fluorinated homocamptothecinsO Lavergne, D Demarquay, C Bailly, et al.Journal of Medicinal Chemistry|January 6, 1999
Homocamptothecins: synthesis and antitumor activity of novel E-ring-modified camptothecin analoguesO Lavergne, L Lesueur-Ginot, F Pla Rodas, et al.Pageof 2